醒脑静治疗中重度急性缺血性卒中(XMAS):随机对照试验研究方案
XMAS 是一项多中心、前瞻性、随机对照、开放标签、终点盲法评估的试验,计划纳入 720 例急性缺血性卒中患者,按 1:1 随机分配接受醒脑静注射液联合标准治疗或单纯标准治疗,醒脑静每 12 小时静脉给药一次、连续 10 天。主要结局为发病 3 个月时改良 Rankin 量表评分 0 至 2 分的独立患者比例。
要点
- 醒脑静在中国广泛用于卒中治疗,但目前缺乏其治疗急性缺血性卒中的高质量疗效证据。
- 试验计划纳入 720 例中重度急性缺血性卒中患者,按 1:1 随机分组,醒脑静每 12 小时静脉给药一次、连续 10 天。
- 主要结局为发病 3 个月时改良 Rankin 量表评分 0 至 2 分的独立患者比例。
核心结论
- 该试验结果将为醒脑静作为再灌注治疗后或不适于溶栓治疗的急性缺血性卒中的补充治疗方法提供关键证据。
研究设计与样本
- XMAS 研究是一项多中心、前瞻性、随机对照、开放标签、终点盲法评估的试验。
- 计划共纳入 720 例患者,按 1:1 比例随机分配至干预组或对照组。
- 干预组接受醒脑静联合标准治疗,对照组仅接受标准治疗。
- 醒脑静每 12 小时静脉给药一次,连续 10 天。
关键数值与推荐
- 主要结局为发病 3 个月时改良 Rankin 量表评分 0 至 2 分的独立患者比例。
- 次要结局包括 48 小时早期神经功能恶化、美国国立卫生研究院卒中量表评分变化、患者报告结局、10 天症状性颅内出血、Barthel 指数评分、3 个月全因死亡和心血管事件。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Xingnaojing injection (XNJ) is widely used for the treatment of stroke in China. However, there is currently a lack of high-quality evidence of its efficacy for acute ischemic stroke. The main objective of this study is to determine whether the addition of XNJ to standard care improves the 3-month functional outcome in patients with acute ischemic stroke (AIS). METHODS/DESIGN: The XMAS study is a multicenter, prospective, randomized controlled, open-label trial with a blinded endpoints design. A total of 720 patients will be randomly allocated to either the intervention or the control group in a 1:1 ratio. The intervention group receives XNJ combined with standard care, and the control group receives standard care alone. XNJ will be administered intravenously every 12 h for 10 days. The primary outcome is the proportion of patients who are independent at 3 months after stroke onset defined as a modified Rankin Scale score of 0 to 2. Secondary outcomes include early neurological deterioration at 48 h, the change in National Institutes of Health Stroke Scale score, patient-reported outcome, symptomatic intracranial hemorrhage at 10 days, the Barthel Index score, deaths from any cause and cardiovascular events at 3 months. DISCUSSION: The results of this trial will provide critical evidence for XNJ in the treatment of AIS as a complementary approach that can be initiated after reperfusion therapy or when the AIS is not eligible for thrombolytic treatment. TRIAL REGISTRATION: Clinical Trials.gov, ID: NCT02728180 . Registered on 28 March 2016.
引用
- Lai X, Cao K, Kong L, et al. Xingnaojing for Moderate-to-severe Acute ischemic Stroke (XMAS): study protocol for a randomized controlled trial. Trials. 2017. PMID: 29037226. doi:10.1186/s13063-017-2222-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。